The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis
The safety profile of interleukin-1 receptor antagonist (anakinra) has been studied with randomised, placebo-controlled trials involving 2932 patients affected by rheumatoid arthritis. The most frequently reported adverse events were represented by injection site reactions (71%) and headache (13.6%)...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-09-01
|
| Series: | Reumatismo |
| Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/191 |
| _version_ | 1818008300598329344 |
|---|---|
| author | L. Riente |
| author_facet | L. Riente |
| author_sort | L. Riente |
| collection | DOAJ |
| description | The safety profile of interleukin-1 receptor antagonist (anakinra) has been studied with randomised, placebo-controlled trials involving 2932 patients affected by rheumatoid arthritis. The most frequently reported adverse events were represented by injection site reactions (71%) and headache (13.6%). No statistically significant difference in the incidence of infections was observed among the patients treated with the interleukin-1 receptor antagonist and the patients receiving placebo. In particular, the incidence of serious infections was 1,8% in rheumatoid arthritis patients on anakinra therapy and 0,7% in patients on placebo. The reported serious infections consisted of pneumonia, cellulitis, bone and joint infections, bursitis. No case of opportunistic infections or tubercolosis was observed. The results of clinical studies suggest that anakinra is a new well-tolerated drug for the treatment of patients affected by rheumatoid arthritis. |
| first_indexed | 2024-04-14T05:27:21Z |
| format | Article |
| id | doaj.art-93411482bc6144859fb2baf98580a51e |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-04-14T05:27:21Z |
| publishDate | 2011-09-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-93411482bc6144859fb2baf98580a51e2022-12-22T02:09:55ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-01561s747910.4081/reumatismo.2004.1s.74The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritisL. RienteThe safety profile of interleukin-1 receptor antagonist (anakinra) has been studied with randomised, placebo-controlled trials involving 2932 patients affected by rheumatoid arthritis. The most frequently reported adverse events were represented by injection site reactions (71%) and headache (13.6%). No statistically significant difference in the incidence of infections was observed among the patients treated with the interleukin-1 receptor antagonist and the patients receiving placebo. In particular, the incidence of serious infections was 1,8% in rheumatoid arthritis patients on anakinra therapy and 0,7% in patients on placebo. The reported serious infections consisted of pneumonia, cellulitis, bone and joint infections, bursitis. No case of opportunistic infections or tubercolosis was observed. The results of clinical studies suggest that anakinra is a new well-tolerated drug for the treatment of patients affected by rheumatoid arthritis.http://www.reumatismo.org/index.php/reuma/article/view/191 |
| spellingShingle | L. Riente The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis Reumatismo |
| title | The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis |
| title_full | The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis |
| title_fullStr | The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis |
| title_full_unstemmed | The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis |
| title_short | The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis |
| title_sort | safety of interleukin 1 receptor antagonist anakinra in the treatment of rheumatoid arthritis |
| url | http://www.reumatismo.org/index.php/reuma/article/view/191 |
| work_keys_str_mv | AT lriente thesafetyofinterleukin1receptorantagonistanakinrainthetreatmentofrheumatoidarthritis AT lriente safetyofinterleukin1receptorantagonistanakinrainthetreatmentofrheumatoidarthritis |